Electrocardiographic criteria for LVH are, however, not very sensitive, while the alternative more accurate method of echocardiography is uneconomical, especially in resource-limited countries.3 Besides requiring more expertise, the results may not be adequate in all patients, especially in those with obesity or pulmonary disease.4 This situation has led to research on the use of biomarkers such as NT-proBNP and BNP in the detection of the presence of LVH and monitoring its regression.5 The gene discussed is NPPB; the disease is obesity due to melanocortin 4 receptor deficiency.